Nektar Therapeutics (NKTR) to Release Earnings on Thursday

Key Points

• Nektar Therapeutics (NKTR) is scheduled to announce its Q2 2025 earnings on August 7th, with expected earnings of ($2.58) per share and revenue of $9.42 million.
($3.30) per share, missing estimates, alongside a significant negative return on equity of -329.54%.
• Analysts have recently increased their price targets for Nektar Therapeutics, with some raising targets to as high as $120.00, reflecting a generally positive outlook despite recent setbacks.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($2.58) per share and revenue of $9.42 million for the quarter.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.70) by ($0.60). Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. The business had revenue of $10.46 million for the quarter, compared to analyst estimates of $15.61 million. During the same period last year, the firm earned ($2.70) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR traded up $1.16 during trading on Friday, hitting $22.84. 205,524 shares of the company were exchanged, compared to its average volume of 867,194. Nektar Therapeutics has a 12-month low of $6.45 and a 12-month high of $37.38. The company has a fifty day moving average price of $18.18 and a 200-day moving average price of $13.76. The firm has a market capitalization of $283.46 million, a PE ratio of -2.37 and a beta of 0.94.

Hedge Funds Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics in the first quarter valued at approximately $68,000. Rhumbline Advisers lifted its stake in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after buying an additional 41,948 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company's stock valued at $2,463,000 after buying an additional 2,807,595 shares during the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. B. Riley boosted their price objective on shares of Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. BTIG Research boosted their price target on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. HC Wainwright boosted their price target on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Finally, Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.33.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.